Article thumbnail

Blockade of Neuronal α7-nAChR by α-Conotoxin ImI Explained by Computational Scanning and Energy Calculations

By Rilei Yu, David J. Craik and Quentin Kaas


α-Conotoxins potently inhibit isoforms of nicotinic acetylcholine receptors (nAChRs), which are essential for neuronal and neuromuscular transmission. They are also used as neurochemical tools to study nAChR physiology and are being evaluated as drug leads to treat various neuronal disorders. A number of experimental studies have been performed to investigate the structure-activity relationships of conotoxin/nAChR complexes. However, the structural determinants of their binding interactions are still ambiguous in the absence of experimental structures of conotoxin-receptor complexes. In this study, the binding modes of α-conotoxin ImI to the α7-nAChR, currently the best-studied system experimentally, were investigated using comparative modeling and molecular dynamics simulations. The structures of more than 30 single point mutants of either the conotoxin or the receptor were modeled and analyzed. The models were used to explain qualitatively the change of affinities measured experimentally, including some nAChR positions located outside the binding site. Mutational energies were calculated using different methods that combine a conformational refinement procedure (minimization with a distance dependent dielectric constant or explicit water, or molecular dynamics using five restraint strategies) and a binding energy function (MM-GB/SA or MM-PB/SA). The protocol using explicit water energy minimization and MM-GB/SA gave the best correlations with experimental binding affinities, with an R2 value of 0.74. The van der Waals and non-polar desolvation components were found to be the main driving force for binding of the conotoxin to the nAChR. The electrostatic component was responsible for the selectivity of the various ImI mutants. Overall, this study provides novel insights into the binding mechanism of α-conotoxins to nAChRs and the methodological developments reported here open avenues for computational scanning studies of a rapidly expanding range of wild-type and chemically modified α-conotoxins

Topics: Research Article
Publisher: Public Library of Science
OAI identifier:
Provided by: PubMed Central

To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.

Suggested articles


  1. (1994). A nicotinic acetylcholine receptor ligand of unique specificity, a-conotoxin ImI.
  2. (2003). A structural model of agonist binding to the a3b4 neuronal nicotinic receptor.
  3. (2010). A synthetic combinatorial strategy for developing a-conotoxin analogs as potent a7 nicotinic acetylcholine receptor antagonists.
  4. (2004). a-conotoxins ImI and ImII target distinct regions of the human a7 nicotinic acetylcholine receptor and distinguish human nicotinic receptor subtypes.
  5. (2001). a-Conotoxins: nicotinic acetylcholine receptor antagonists as pharmacological tools and potential drug leads.
  6. (1995). aConotoxin ImI exhibits subtype-specific nicotinic acetylcholine receptor blockade: preferential inhibition of homomeric a 7a n da 9 receptors.
  7. (2008). AMBER 10. San Francisco:
  8. (2003). Asymmetric structural motions of the homomeric a7 nicotinic receptor ligand binding domain revealed by molecular dynamics simulation.
  9. (2006). Brain nicotinic acetylcholine receptors: native subtypes and their relevance.
  10. (2007). Central nicotinic receptors: structure, function, ligands, and therapeutic potential.
  11. (2007). Chemical modification of conotoxins to improve stability and activity.
  12. (1993). Comparative protein modelling by satisfaction of spatial restraints.
  13. (2010). Conopeptide characterization and classifications: an analysis using ConoServer.
  14. (2005). Conotoxins and the posttranslational modification of secreted gene products.
  15. (2009). Conotoxins: natural product drug leads.
  16. (1999). Conus peptides targeted to specific nicotinic acetylcholine receptor subtypes.
  17. (2004). Conus venoms: a rich source of novel ion channel-targeted peptides.
  18. (2007). Crystal structure of the extracellular domain of nAChR a1 bound to a-bungarotoxin at 1.94 A resolution.
  19. (2004). Determination of aconotoxin binding modes on neuronal nicotinic acetylcholine receptors.
  20. (1990). Diversity of Conus neuropeptides.
  21. (2006). Dynamical properties of the soft sticky dipole-quadrupole-octupole water model: a molecular dynamics study.
  22. (2002). Emerging structure of the nicotinic acetylcholine receptors.
  23. (2004). Exploring protein native states and large-scale conformational changes with a modified generalized born model.
  24. (2010). Fast and accurate predictions of binding free energies using MM-PBSA and MM-GBSA.
  25. (1998). Functional determinants by which snake and cone snail toxins block the a7 neuronal nicotinic acetylcholine receptors.
  26. (2010). Gating of nicotinic ACh receptors: latest insights into ligand binding and function.
  27. (2007). Heterogeneity and complexity of native brain nicotinic receptors.
  28. (2009). Interpretation of the binding affinities of PTP1B inhibitors with the MM-GB/SA method and the X-score scoring function.
  29. (1997). LINCS: A linear constraint solver for molecular simulations.
  30. (2009). Longrange coupling in an allosteric receptor revealed by mutant cycle qnalysis.
  31. (2008). Mechanics of channel gating of the nicotinic acetylcholine receptor.
  32. (1999). Minimal conformation of the a-conotoxin ImI for the a7 neuronal nicotinic acetylcholine receptor recognition: correlated CD, NMR and binding studies.
  33. (2002). Models of the extracellular domain of the nicotinic receptors and of agonist- and Ca 2+-binding sites.
  34. (2010). Molecular basis of the interaction for an essential subunit PA2PB1 in influenza virus RNA polymerase: insights from molecular dynamics simulation and free energy calculation.
  35. (1999). Molecular dynamics simulations of biomolecules: long-range electrostatic effects.
  36. (2009). Molecular modeling of the a9a10 nicotinic acetylcholine receptor subtype.
  37. (2010). MolProbity: all-atom structure validation for macromolecular crystallography.
  38. (2004). MUSCLE: a multiple sequence alignment method with reduced time and space complexity.
  39. (2007). Neuronal nicotinic receptors: a perspective on two decades of drug discovery research.
  40. (2009). Nicotinic receptors: allosteric transitions and therapeutic targets in the nervous system.
  41. (1999). NMR spatial structure of a-conotoxin ImI reveals a common scaffold in snail and snake toxins recognizing neuronal nicotinic acetylcholine receptors.
  42. (1999). Pairwise interactions between neuronal a7 acetylcholine receptors and a-conotoxin ImI.
  43. (2010). Pe ´rez-Cano L, Ferna ´ndez-Recio J
  44. (1985). Peptide neurotoxins from fish-hunting cone snails.
  45. (2007). Protein folding determinants: structural features determining alternative disulfide pairing in aand k/l-conotoxins.
  46. (2009). Rational design of a-conotoxin analogues targeting a7 nicotinic acetylcholine receptors: improved antagonistic activity by incorporation of proline derivatives.
  47. (2005). Refined structure of the nicotinic acetylcholine receptor at 4A resolution.
  48. Rezvani AH (2007) Nicotinic interactions with antipsychotic drugs, models of schizophrenia and impacts on cognitive function.
  49. (2009). Rodent habenulo-interpeduncular pathway expresses a large variety of uncommon nAChR subtypes, but only the a3b4* and a3b3b4* subtypes mediate acetylcholine release.
  50. (2009). Scanning mutagenesis of a-conotoxin Vc1.1 reveals residues crucial for activity at the a9a10 nicotinic acetylcholine receptor.
  51. (1999). Solution structure of aconotoxin ImI by 1H nuclear magnetic resonance.
  52. (1983). Solvent-accessible surfaces of proteins and nucleic acids.
  53. (2008). Spontaneous conformational change and toxin binding in a7 acetylcholine receptor: insight into channel activation and inhibition.
  54. (1992). Stereochemical quality of protein structure coordinates.
  55. (2006). Structural determinants of selective a-conotoxin binding to a nicotinic acetylcholine receptor homolog AChBP.
  56. (1998). Structural elements in a-conotoxin ImI essential for binding to neuronal a7 receptors.
  57. (2000). Structure-activity relationships in a peptidic a7 nicotinic acetylcholine receptor antagonist.
  58. (2005). Structures of Aplysia AChBP complexes with nicotinic agonists and antagonists
  59. (2006). Targeted molecular dynamics study of C-loop closure and channel gating in nicotinic receptors.
  60. (2004). The Cys-loop superfamily of ligand-gated ion channels: the impact of receptor structure on function.
  61. (2010). The structural basis of peptide-protein binding strategies.
  62. (2000). Theory and applications of the generalized born solvation model in macromolecular simulations.
  63. (2001). Use of MM-PBSA in reproducing the binding free energies to HIV-1 RT of TIBO derivatives and predicting the binding mode to HIV-1 RT of efavirenz by docking and MMPBSA.